2. Academic Validation
  3. Interleukin 28 is a potential therapeutic target for sepsis

Interleukin 28 is a potential therapeutic target for sepsis

  • Clin Immunol. 2019 Aug;205:29-34. doi: 10.1016/j.clim.2019.05.012.
Qin Luo 1,  Yi Liu 2,  Shuang Liu 3,  Yibing Yin 3,  Banglao Xu 4,  Ju Cao 5
Affiliations

Affiliations

  • 1 Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
  • 2 Department of Intensive Care Unit, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • 3 Key Laboratory of Diagnostic Medicine designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.
  • 4 Department of Laboratory Medicine, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China.
  • 5 Department of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: [email protected].
PMID: 31121287 DOI: 10.1016/j.clim.2019.05.012
Abstract

Identification of new therapeutic targets for the treatment of sepsis is imperative. We report here that cytokine IL-28 (IFN-λ) levels were elevated in clinical and experimental sepsis. Neutralization of IL-28 protected mice from lethal sepsis induced by cecal ligation and puncture (CLP), which was associated with improved Bacterial clearance and enhanced neutrophil infiltration. Conversely, administration of recombinant IL-28 aggravated mortality, facilitated Bacterial dissimilation and limited neutrophil recruitment, in the model of sepsis induced by CLP. This study defines IL-28 as a detrimental mediator during sepsis and identifies a potential therapeutic target for the immune therapy in sepsis.

Keywords

Immunity; Infection; Interleukin-28; Neutrophil; Sepsis.

Figures
Products